Patrick Kirby
Vice President, Toxicology at Dragonfly Therapeutics, Inc.
Professional Overview
Patrick Kirby is a seasoned toxicology expert with over 20 years of experience in the pharmaceutical industry. As the Vice President of Toxicology at Dragonfly Therapeutics, Inc., he oversees the company's toxicology program, ensuring the safety and efficacy of their innovative therapeutic candidates.
Experience Summary
Current Role
In his current position, Patrick is responsible for leading the toxicology team and designing and executing preclinical studies to support the advancement of Dragonfly's pipeline. He collaborates closely with cross-functional partners to provide strategic insights and data-driven recommendations that inform critical decision-making. Under his leadership, the toxicology team has successfully navigated numerous regulatory interactions and contributed to the progression of several drug candidates to clinical development.
Career Progression
Prior to joining Dragonfly, Patrick held senior toxicology roles at leading pharmaceutical companies, including Sanofi, Alnylam Pharmaceuticals, and Takeda Pharmaceuticals. He has a proven track record of driving innovative research, managing complex projects, and building high-performing teams. Throughout his career, Patrick has contributed to the development of several FDA-approved therapies, showcasing his ability to navigate the regulatory landscape and deliver tangible results.
Academic Background
Patrick holds a Bachelor of Science degree in Biology from the University of Massachusetts Amherst. He has also completed postgraduate studies in toxicology at the Harvard School of Public Health, where he conducted research focused on the evaluation of environmental exposures and their impact on human health.
Areas of Expertise
- Preclinical toxicology study design and execution
- Regulatory strategy and compliance
- Translational research and biomarker development
- Cross-functional collaboration and team leadership
- Risk assessment and risk mitigation strategies
Professional Impact
Over the course of his career, Patrick has made significant contributions to the advancement of several novel therapeutic candidates. He has played a key role in securing regulatory approvals, leading to the successful commercialization of therapies that have improved patient outcomes. Additionally, Patrick has been recognized for his commitment to mentoring and developing talent within the toxicology field.
Conclusion
With his extensive experience, technical expertise, and proven leadership abilities, Patrick Kirby is a valuable asset to Dragonfly Therapeutics. In his role as Vice President of Toxicology, he continues to drive innovation and ensure the safety and efficacy of the company's therapeutic pipeline, contributing to the development of transformative therapies that have the potential to improve the lives of patients worldwide.
